Cytokinetics, Incorporated (Nasdaq: CYTK) announced today positive results from the first cohort, or Part A, of a continuing Phase II clinical trial of CK-2017357 in patients with amyotrophic lateral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback